In reply:

Obstetrics and Gynecology

Volumn 118, Issue 3, 2011, Pages 708-709

  Yonkers, Kimberly A ^a   Vigod, Simone ^b   Ross, Lori E ^b  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF TORONTO   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

SEROTONIN UPTAKE INHIBITOR;

DRUG APPROVAL; HUMAN; LETTER; MAJOR DEPRESSION; MATERNAL TREATMENT; NEWBORN DISEASE; PREGNANCY DISORDER; PREMATURITY; PRIORITY JOURNAL; PSYCHIATRIC TREATMENT; PSYCHOTHERAPY; PULMONARY HYPERTENSION; TREATMENT INDICATION;

EID: 80052151198     PISSN: 00297844     EISSN: None     Source Type: Journal    
DOI: 10.1097/AOG.0b013e31822bdb8d     Document Type: Letter

References (5)

1. Yonkers KA, Vigod S, Ross LE. Diagnosis, pathophysiology, and management of mood disorders in pregnant and postpartum women. Obstet Gynecol 2011;117: 961-977.
2. Yonkers KA, Wisner KL, Stewart DE, Oberlander TF, Dell DL, Stotland N, et al. The management of depression during pregnancy: a report from the American Psychiatric Association and the American College of Obstetricians and Gynecologists. Obstet Gynecol 2009;114:703-713.
3. Alwan S, Reefhuis J, Rasmussen SA, Olney RS, Friedman JM, the National Birth Defects Prevention Study. Use of selective serotonin-reuptake inhibitors in pregnancy and the risk of birth defects. N Engl J Med 2007;356:2684-692. (Pubitemid 47001036)
4. Louik C, Lin AE, Werler MM, Hernandez-Diaz S, Mitchell AA. First-trimester use of selective serotonin-reuptake inhibitors and the risk of birth defects. N Engl J Med 2007;356:2675-683. (Pubitemid 47001035)
5. Moses-Kolko EL, Bogen D, Perel J, Bregar A, Uhl K, Levin B, et al. Neonatal signs after late in utero exposure to serotonin reuptake inhibitors: literature review and implications for clinical applications. JAMA 2005;293:2372-383. (Pubitemid 40676760)